Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 7, 2014; 20(13): 3391-3400
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3391
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3391
Challenges of recurrent hepatitis C in the liver transplant patient
Renumathy Dhanasekaran, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55901, United States
Roberto J Firpi, Division of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, FL 32610, United States
Author contributions: Dhanasekaran R wrote the manuscript; Firpi RJ conceptualized the paper, edited the manuscript and supervisor.
Correspondence to: Roberto J Firpi, MD, MS, Associate Professor, Division of Gastroenterology, Hepatology and Nutrition, University of Florida, 1600 SW Archer Rd, MSB M440, Gainesville, FL 32610, United States. roberto.firpi@medicine.ufl.edu
Telephone: +1-352-2739500 Fax: +1-352-3927393
Received: September 29, 2013
Revised: November 22, 2013
Accepted: March 7, 2014
Published online: April 7, 2014
Processing time: 186 Days and 15.2 Hours
Revised: November 22, 2013
Accepted: March 7, 2014
Published online: April 7, 2014
Processing time: 186 Days and 15.2 Hours
Core Tip
Core tip: Management of recurrent hepatitis C in post-transplant patient is challenging but can be rewarding as treatment has been shown to improve survival and slow fibrosis progression. This review summarizes major challenges in this population and discusses the natural history of post-transplant Hepatitis C virus (HCV), risk factors for HCV recurrence, management of immunosuppression and current treatment options. The preliminary data on use of newer direct acting antiviral drugs in the post-transplant setting has also been included.